Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Published Online: 2022-06-?
Journal: The Lancet•Publisher: Elsevier BV
Authors: Alessandro Crotta•Alessandro Previtali•Bertram Glass•David G Maloney•Francisco Hernandez-Ilizaliturri•Franck Morschhauser•Jeremy S Abramson•Jon Arnason•Ken Ogasawara•Koji Izutsu•Lara Stepan•Manali Kamdar•Matthew Lunning•Patrick B Johnston•Pim Mutsaers•Sami Ibrahimi•Sandrine Montheard•Scott R Solomon•Stephan Mielke•Timothy Mack•Veronika Bachanova
